title: Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
abstract: This predefined analysis of the European Forsteo Observational Study (EFOS) aimed to describe clinical fracture incidence, back pain, and health-related quality of life (HRQoL) during 18 months of teriparatide treatment and 18 months post-teriparatide in the subgroup of 589 postmenopausal women with osteoporosis aged ≥75 years. Data on clinical fractures, back pain (visual analogue scale, VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. A repeated-measures model analyzed changes from baseline in back pain VAS and EQ-VAS. During the 36-month observation period, 87 (14.8 %) women aged ≥75 years sustained a total of 111 new fractures: 37 (33.3 %) vertebral fractures and 74 (66.7 %) nonvertebral fractures. Adjusted odds of fracture was decreased by 80 % in the 30 to <36-month interval compared with the first 6-month interval (P < 0.009). Although the older subgroup had higher back pain scores and poorer HRQoL at baseline than the younger subgroup, both age groups showed significant reductions in back pain and improvements in HRQoL postbaseline. In conclusion, women aged ≥75 years with severe postmenopausal osteoporosis treated with teriparatide in normal clinical practice showed a reduced clinical fracture incidence by 30 months compared with baseline. An improvement in HRQoL and, possibly, an early and significant reduction in back pain were also observed, which lasted for at least 18 months after teriparatide discontinuation when patients were taking other osteoporosis medication. The results should be interpreted in the context of an uncontrolled observational study.
authors.affiliation: St. James's Hospital and Trinity College, Dublin, Ireland.
authors.forename: J Bernard
authors.initials: JB
authors.lastname: Walsh
authors.forename: Willem F
authors.initials: WF
authors.lastname: Lems
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Karras
authors.forename: Bente L
authors.initials: BL
authors.lastname: Langdahl
authors.forename: Osten
authors.initials: O
authors.lastname: Ljunggren
authors.forename: Astrid
authors.initials: A
authors.lastname: Fahrleitner-Pammer
authors.forename: Annabel
authors.initials: A
authors.lastname: Barrett
authors.forename: Gerald
authors.initials: G
authors.lastname: Rajzbaum
authors.forename: Franz
authors.initials: F
authors.lastname: Jakob
authors.forename: Fernando
authors.initials: F
authors.lastname: Marin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001416:Back Pain / Q000209:etiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D016015:Logistic Models; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D019379:Teriparatide / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide